Patients prefer ViiV’s PrEP jab over Gilead’s – study
The long-acting HIV prevention jab cabotegravir has a higher acceptability rating among patients than lenacapavir, according to a study. ViiV Healthcare, a global specialist HIV…
Glax
Hot Topics
- March 9, 2026 | Real-time data on global dengue outbreaks
- November 5, 2025 | Davos brain health plan hopes to unlock Africa funds
- October 31, 2025 | GSK’s Q3 results buoyed by long-acting HIV jab
- October 27, 2025 | South Africa to make Gilead’s lenacapavir a ‘public good’
- October 24, 2025 | Sanofi Global Health Unit says 1 mln reached since 2021